LEXINGTON, Mass., Oct. 26, 2017 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, will release
its third quarter 2017 financial results before the market opens on
Tuesday, November 7, 2017. Agenus
executives will host a conference call and webcast at 11:00 a.m. ET the same day.
To access the live call, dial 1-844-492-3727 (U.S.) or
1-412-317-51181 (International) and ask to be joined into the
Agenus call. The call will also be webcast and will be accessible
from the Company's website at
http://investor.agenusbio.com/presentation-webcasts or with this
link https://www.webcaster4.com/Webcast/Page/1556/23075. A replay
will be available on the Company's website approximately two hours
after the call and will remain available for 90 days.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing a number of combination approaches that leverage a broad
repertoire of antibody therapeutics and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For
more information, please visit www.agenusbio.com; information that
may be important to investors will be routinely posted on our
website.
Forward-Looking Statement
This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding Agenus' anticipated timing for releasing
its third quarter 2017 financial results. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenbio.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-to-report-third-quarter-2017-financial-results-on-november-7-2017-and-host-conference-call-and-webcast-300544153.html
SOURCE Agenus